|
|
|
| Relationship between serum IL-1β, IL-17 levels and the therapeutic effect in patients with first-episode schizophrenia |
| YAN Ci1 WANG Yanbo2 |
1.Department of Psychiatry, Hangzhou Seventh People′s Hospital, Zhejiang Province, Hangzhou 310000, China;
2.the Third Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou 310000, China |
|
|
|
Abstract Objective To explore the relationship between serum interleukin-1β (IL-1β), interleukin-17 (IL-17) levels and the therapeutic effect in patients with first-episode schizophrenia. Methods A total of 200 patients with first-episode schizophrenia admitted in Hangzhou Seventh People′s Hospital from January 2017 to January 2019 were selected as the research group. Olanzapine was given to the patients on the day of admission and the treatment time was 4 weeks. At the same time, sixty healthy people were selected as the control group. The positive and negative symptoms scale (PANSS) scores were recorded before and 4 weeks after treatment. The serum IL-1β and IL-17 levels of two groups were measured by enzyme-linked immunosorbent assay. According to the effective rate of treatment, the research group was divided into group A (recovery, 30 cases), group B (significant progress, 60 cases), group C (improvement, 72 cases) and group D (ineffective, 38 cases). The serum IL-1β and IL-17 levels were compared before and after treatment in each group. Pearson correlation was used to analyze the correlation between serum IL-1β, IL-17 levels and PANSS score in patients. Results The levels of serum IL-1β and IL-17 in the research group were higher than those in the control group, and the differences were statistically significant (P ＜ 0.05). The levels of serum IL-1β and IL-17 in the research group after treatment were significantly lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). Compared with before treatment in the same group, the serum levels of IL-1β in groups A, B and C were significantly reduced, and the serum levels of IL-17 in groups A and B were significantly reduced, the differences were statistically significant (P ＜ 0.05). Further pairwise comparison, the differences in serum IL-1β levels of the four groups were statistically significant (P ＜ 0.05), and the level in group A was the lowest. In addition, the serum IL-17 levels in group A were significantly lower than those in the other three groups, and the serum IL-17 levels in group B were significantly lower than those in group D, and the differences were statistically significant (P ＜ 0.05). The levels of serum IL-1β and IL-17 were positively correlated with PANSS score（r = 0.386, 0.544, P ＜ 0.05）. Conclusion IL-1β and IL-17 are closely related to the onset of schizophrenia, which can reflect the therapeutic effect to a certain extent, and have an important value in evaluating clinical effect of patients.
|
|
|
|
|
|
[1] 王莹，边艳辉，江芮.奥氮平与利培酮治疗精神分裂症患者认知功能的疗效比较[J].中国药房，2017，28（36）：5083-5086.
[2] 何思维，方蓉.氯氮平联合利培酮对老年精神分裂症阳性症状患者血清T淋巴细胞亚群及炎症因子水平的影响[J].医学临床研究，2018，35（8）：1588-1590.
[3] 黄飞，姜祥智.炎性标记物预测首发精神分裂症治疗应答的临床研究[J].青岛大学医学院学报，2017，2（4）：90-92，95.
[4] 殷军波，成媛媛，孙丕健，等.齐拉西酮替换利培酮治疗精神分裂症的疗效及安全性研究[J].精神医学杂志，2016， 29（5）：366-368.
[5] 戴云飞，肖泽萍.中国精神障碍分类与诊断标准第3版与国际疾病分类第10版的比较[J].临床精神医学杂志，2013，23（6）：426-427.
[6] Miyamoto S，Duncan GE，Marx CE，et al. Treatments for schizophrenia ：a critical review of pharmacology and mechanisms of action of antipsychotic drugs [J]. Molecular psychiatry，2005，10（1）：79.
[7] 隗春玲.不同剂量利培酮治疗首发精神分裂症的疗效观察[J].现代药物与临床，2015，30（11）：1386-1389.
[8] 占瑾琼，余斌，康光宇，等.7,8-二羟基黄酮对精神分裂症模型大鼠空间认知及海马突触结构的影响[J].医药导报，2017，36（10）：1153-1157.
[9] 张绮航，周福春，王传跃.精神分裂症各临床症状维度与炎症免疫机制[J].国际精神病学杂志，2019，46（2）：193-195，205.
[10] Howes OD，Mccutcheon R. Inflammation and the neural diathesis-stress hypothesis of schizophrenia：a reconceptualization [J]. Transl Psychiatry，2017，7（2）：e1024.
[11] 代文瑾，张媛，尚翠华，等.急性发作精神分裂症患者血清前炎性因子与临床特征的关系[J].神经疾病与精神卫生，2017，17（8）：558-561.
[12] 张玖龙.免疫在精神分裂症发病和治疗中的研究进展[J].神经疾病与精神卫生，2017，17（7）：528-530.
[13] 代文瑾，贾强，冯薇，等.稳定期精神分裂症患者血浆促炎细胞因子水平与临床症状的相关研究[J].中国心理卫生杂志，2019，33（4）：48-50.
[14] 马骏，孙梦夕，张琳，等.首发精神分裂症患者治疗效果与血清炎性因子水平变化关系研究[J].新乡医学院学报，2017，34（2）：113-116.
[15] Mendiola AS，Cardona AE. The IL-1β phenomena in neuroinflammatory diseases [J]. J Neural Transm，2017， 25（5）：781-795.
[16] 王美玲，王继才，白燕.IL-23/IL-17免疫轴在精神分裂症中的作用[J].国际精神病学杂志，2018，45（2）：211-212，226.
[17] 陈传刚，王静，尹晓煜，等.精神分裂症患者血清细胞因子水平变化及其与病情的关系[J].山东医药，2016，56（8）：89-90.
[18] 张志滨，傅春恋，郭轶，等.奥氮平用于维持性精神分裂症治疗的临床效果[J].中国医药科学，2017，7（16）：32-34.
[19] 黄桥生，徐止浩.补肾健脑方联合奥氮平治疗精神行为障碍老年痴呆疗效观察[J].现代中西医结合杂志，2019， 28（24）：2701-2703，2713.
[20] 何思维，方蓉.氯氮平联合利培酮对老年精神分裂症阳性症状患者血清T淋巴细胞亚群及炎症因子水平的影响[J].医学临床研究，2018，35（8）：1588-1590.
[21] 孙洪波，薛欣杰，燕银枝，等.奥氮平联合氨磺必利治疗难治性精神分裂症的效果研究[J].中国医药科学，2018， 8（23）：214-217.
[22] 方新宇，张晨.白介素17与精神分裂症的相关性研究进展[J].上海交通大学学报：医学版，2017，37（9）：1265-1269. |
|
|
|
